| Drug General Information |
| Drug ID |
D05ATQ
|
| Former ID |
DIB004881
|
| Drug Name |
MVA HER-2 AutoVac
|
| Synonyms |
MVA-BN HER-2 AutoVac; MVA-BN-HER2; PX-103.2; MVA-BN Breast (cancer vaccine), Bavarian Nordic; MVA-BN breast cancer vaccine, BN ImmunoTherapeutics/ Pharmexa; MVA-BN/Her-2/Neu
|
| Drug Type |
Vaccine
|
| Indication |
Breast cancer [ICD9: 174, 175; ICD10:C50]
|
Phase 1 |
[1]
|
|---|
| Company |
Pharmexa A/S
|
| Target and Pathway |
| Target(s) |
Receptor protein-tyrosine kinase erbB-2 |
Target Info |
|
[2]
|
|---|
|
KEGG Pathway
|
ErbB signaling pathway
|
|
Calcium signaling pathway
|
|
HIF-1 signaling pathway
|
|
Focal adhesion
|
|
Adherens junction
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Prostate cancer
|
|
Bladder cancer
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Cadherin signaling pathway
|
|
EGF receptor signaling pathway
|
|
Pathway Interaction Database
|
ErbB4 signaling events
|
|
ErbB2/ErbB3 signaling events
|
|
ErbB receptor signaling network
|
|
a6b1 and a6b4 Integrin signaling
|
|
Validated targets of C-MYC transcriptional repression
|
|
PathWhiz Pathway
|
Phosphatidylinositol Phosphate Metabolism
|
|
Reactome
|
SHC1 events in ERBB2 signaling
|
|
PLCG1 events in ERBB2 signaling
|
|
PIP3 activates AKT signaling
|
|
GRB2 events in ERBB2 signaling
|
|
PI3K events in ERBB2 signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
Sema4D induced cell migration and growth-cone collapse
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
ErbB Signaling Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
Focal Adhesion
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Bladder Cancer
|
|
Signaling by ERBB2
|
|
Integrated Pancreatic Cancer Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
Leptin signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
Semaphorin interactions
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01152398) A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy. U.S. National Institutes of Health. |
|---|
| REF 2 | Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol. 2013 Jul;24(7):1740-8. |
|---|
